3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
22
Lymphoma, Follicular
14
Lymphoma, B-Cell, Marginal Zone
11
Lymphoma
11
Lymphoma, Mantle-Cell
10
Lymphoma, Non-Hodgkin
7
Lymphoma, Large B-Cell, Diffuse
6
Neoplasms
4
Lymphoma, B-Cell
4
Recurrence
3
Burkitt Lymphoma
3
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasm, Residual
1
Melanoma
1
Mature B-cell Malignancies
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Leukemia, Hairy Cell
1
Leukemia, B-Cell
1
Leukemia
1
Heart Failure
1
Extensive Stage Small Cell Lung Cancer
1
Dendritic Cell Sarcoma, Interdigitating
1
Cytokine Release Syndrome
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
Cyclophosphamide
7
venetoclax
6
Azacitidine
6
fludarabine
5
Cytarabine
4
Blood Specimen Collection
4
daratumumab
3
Lenalidomide
3
Daunorubicin
3
tislelizumab
2
fludarabine phosphate
2
Rituximab
2
Liquid Biopsy
2
Idarubicin
2
Gemtuzumab
2
Capecitabine
2
Busulfan
2
trastuzumab deruxtecan
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sugemalimab
1
sacituzumab govitecan
1
relugolix
1
pembrolizumab
1
pegaspargase
1
palbociclib
1
obinutuzumab
1
ivosidenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm, Residual
×
obinutuzumab
×
Clear all
NCT05929222
2026-06-01
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
Phase 3
Recruiting
190 enrolled